Navigation Links
Poniard Pharmaceuticals to Host Conference Call and Webcast at 8:00 a.m. Eastern Time Tomorrow to Discuss Results of Pivotal Phase 3 SPEAR Trial in Small Cell Lung Cancer
Date:11/15/2009

SOUTH SAN FRANCISCO, Calif., Nov. 15 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD) today announced that the Company will hold a teleconference and webcast at 8:00 a.m. Eastern Time tomorrow, Monday, November 16, to discuss results from its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial of picoplatin in patients with small cell lung cancer.

Conference Call and Webcast Information

To participate in the live call on Monday, November 16, at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time), please dial 866-816-1982 from the U.S. or 913-312-0857 for international callers. The Webcast can be accessed on the "Events" page of the "News & Events" section of the Company's Web site at http://www.poniard.com. A replay of the Webcast will be available on the Company's Web site for 10 days.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum chemotherapy. Clinical trials of intravenous picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2 trials in metastatic colorectal and castration-resistant (hormone refractory) prostate cancers. The Company also has conducted a clinical trial of oral picoplatin in solid tumors. For additional information please visit http://www.poniard.com.

(C) 2009 Poniard Pharmaceuticals, Inc. All Rights Reserved.

Poniard and Poniard Pharmaceuticals are trademarks of Poniard Pharmaceuticals, Inc.

SOURCE Poniard Pharmaceuticals, Inc.


'/>"/>
SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Poniard Pharmaceuticals to Present at Two Upcoming Investor Conferences in August
2. Poniard Pharmaceuticals Announces Positive Efficacy and Safety Data From Phase 2 Clinical Trial of Picoplatin in Men With Metastatic Prostate Cancer
3. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
4. Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology
5. Poniard Pharmaceuticals to Focus Company Resources on Late-Stage Oncology Candidate Picoplatin Through Realignment of Research Organization
6. Poniard Pharmaceuticals to Present at Needham & Companys Cancer Therapeutics: Today & Tomorrow Conference
7. Poniard Pharmaceuticals Receives Going Concern Qualification
8. Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer
9. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
10. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
11. Poniard Pharmaceuticals Reports Second Quarter 2008 Financial Results and Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... (PRWEB) , ... May 21, 2017 , ... ... if it's been longer than six months since you've seen a dentist, it's ... twice per year and getting x-rays once per year. , Dental checkups are ...
(Date:5/19/2017)... ... May 19, 2017 , ... When Kyle Busch graduates from ... will already appear on two major research studies that could impact the health of ... Matt Daggett, KCU alumnus and an orthopedic surgeon, alongside an international team trying to ...
(Date:5/19/2017)... ... May 19, 2017 , ... The Arnold ... Young Investigators: , Victor Acosta, Ph.D. - University of New Mexico, Jeremy Baskin, ... - University of Washington, Erik Grumstrup, Ph.D. - Montana Stata University, A. Fatih ...
(Date:5/19/2017)... ... 2017 , ... CloSYS products which are marketed as the gentle giants of ... and gum health, which is linked to one’s overall health. Since 1991 when the ... powerful ways in which CloSYS products immediately helped eliminate bad breath as well as ...
(Date:5/18/2017)... ... ... Originally launched to market as the EPIK Learning Tab, the highly successful ... of their product line, the company believed it was the right time to create ... be any tablet product sold by EPIK Learning. This year there will be ...
Breaking Medicine News(10 mins):
(Date:5/15/2017)... 15, 2017 Enterin Inc., a privately-held CNS pharmaceutical ... novel compounds to treat Parkinson,s disease (PD), has enrolled the ... Phase 1/2a randomized, controlled, multicenter study involving patients with PD ... 50 patients over a 9-to-12-month period. The first stage is ... with PD. Participating sites include Denver , ...
(Date:5/10/2017)... May 10, 2017 Global Health Intelligence ... Latin America , published its 2017 ranking of the ... based on extensive data analysis from GHI,s hospitals database ... database for the region. The GHI database covers 86% of ... more than 130 data points for each institution in key ...
(Date:5/9/2017)... 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... announced it has earned a spot on Forbes, ... Company was ranked among 500 U.S. employers as well ... Equipment and Services. The annual Forbes ... independent survey of over 30,000 employees across 25 industries. ...
Breaking Medicine Technology: